First patient set to receive controversial Biogen Alzheimer’s drug

June 16th, 20210 On Wednesday, a U.S. hospital  will give the first infusion of an expensive, controversial new Alzheimer’s drug from Biogen Inc. before Medicare had even said what it will pay for — and with some doctors upset by its approval last week. The first administration of the drug, Aduhelm, outside of a clinical trial is scheduled to take...

COVID’s second wave underscores the threats facing disabled Americans

December 1st, 20200 The second wave of COVID-19 has arrived with a vengeance. But there's hope on the horizon. Pfizer and Moderna just announced their experimental vaccines proved more than 90 percent effective in clinical trials. People in the highest risk categories — namely, healthcare workers and those with chronic illnesses and disabilities —...